Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “VANDA PHARMACEUTICALS INC.”

96 pharma patents match "VANDA PHARMACEUTICALS INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 96
Index total 30,257
Page 3 / 4

Quick answer

This filtered view shows 96 pharmaceutical patents matching "VANDA PHARMACEUTICALS INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

96 results for “VANDA PHARMACEUTICALS INC.” · 30,257 patents in full index Clear search

  1. US 10610510

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted

  2. US 10611744

    Highly purified pharmaceutical grade tasimelteon

    VANDA PHARMACEUTICALS INC. · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted

  3. US 10610511

    Method of treatment

    VANDA PHARMACEUTICALS INC. · Granted Apr 7, 2020 · Expires Apr 2, 2040

    granted

  4. US 10570453

    Method of predicting a predisposition to QT prolongation

    VANDA PHARMACEUTICALS INC. · Granted Feb 25, 2020 · Expires Feb 20, 2040

    granted

  5. US 10570452

    Method of predicting a predisposition to QT prolongation

    VANDA PHARMACEUTICALS INC. · Granted Feb 25, 2020 · Expires Feb 20, 2040

    granted

  6. US 10563259

    Method of treatment based on polymorphisms of the KCNQ1 gene

    VANDA PHARMACEUTICALS INC. · Granted Feb 18, 2020 · Expires Feb 13, 2040

    granted

  7. US 10563261

    Method of predicting a predisposition to QT prolongation

    VANDA PHARMACEUTICALS INC. · Granted Feb 18, 2020 · Expires Feb 13, 2040

    granted

  8. US 10563260

    Method of predicting a predisposition to QT prolongation

    VANDA PHARMACEUTICALS INC. · Granted Feb 18, 2020 · Expires Feb 13, 2040

    granted

  9. US 10463655

    Method of treatment with tradipitant

    VANDA PHARMACEUTICALS INC. · Granted Nov 5, 2019 · Expires Oct 31, 2039

    granted

  10. US 10449176

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Oct 22, 2019 · Expires Oct 17, 2039

    granted

  11. US 10441580

    Iloperidone for the treatment of schizophrenia

    VANDA PHARMACEUTICALS INC. · Granted Oct 15, 2019 · Expires Oct 10, 2039

    granted

  12. US 10376487

    Method of treatment

    VANDA PHARMACEUTICALS INC. · Granted Aug 13, 2019 · Expires Aug 8, 2039

    granted

  13. US 10272075

    Method and composition for treating an alpha adrenoceptor-mediated condition

    VANDA PHARMACEUTICALS INC. · Granted Apr 30, 2019 · Expires Apr 25, 2039

    granted

  14. US 10272076

    Methods for the administration of iloperidone

    VANDA PHARMACEUTICALS INC. · Granted Apr 30, 2019 · Expires Apr 25, 2039

    granted

  15. US 10265282

    Cancer treatment

    VANDA PHARMACEUTICALS INC. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  16. US 10233142

    Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide

    VANDA PHARMACEUTICALS INC. · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted

  17. US 10179119

    Method of treatment

    VANDA PHARMACEUTICALS INC. · Granted Jan 15, 2019 · Expires Jan 10, 2039

    granted

  18. US 10149829

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Dec 11, 2018 · Expires Dec 6, 2038

    granted

  19. US 10071977

    Highly purifid pharmaceutical grade tasimelteon

    VANDA PHARMACEUTICALS INC. · Granted Sep 11, 2018 · Expires Sep 6, 2038

    granted

  20. US 9987264

    Method and composition for treating a serotonin receptor-mediated condition

    VANDA PHARMACEUTICALS INC. · Granted Jun 5, 2018 · Expires May 31, 2038

    granted

  21. US 9855241

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Jan 2, 2018 · Expires Dec 28, 2037

    granted

  22. US 9850199

    Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide

    VANDA PHARMACEUTICALS INC. · Granted Dec 26, 2017 · Expires Dec 21, 2037

    granted

  23. US 9730910

    Treatment of circadian rhythm disorders

    VANDA PHARMACEUTICALS INC. · Granted Aug 15, 2017 · Expires Aug 10, 2037

    granted

  24. US 9708291

    Intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl)-(2-chlorophenyl)-methanone

    VANDA PHARMACEUTICALS INC. · Granted Jul 18, 2017 · Expires Jul 13, 2037

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.